Ubiquigent — a company focused on enabling and supporting ubiquitin system targeted drug discovery — has been awarded a new grant from Innovate UK.
Investment
The grant forms part of Innovate UK’s Investor Accelerator Pilot and will support a project titled ‘The development of novel compounds to seed a neurodegeneration drug discovery programme’. This programme provides simultaneous grant funding and venture capital investment for early stage projects led by UK companies.
As part of the award the company has received further investment from IP Group and a group of experiences life science investors led by the company’s senior management team to support ongoing business growth.
“This latest grant and investment provides additional support for the advancement of one of our key programmes,” commented Ubiquigent’s newly appointed managing director, Jason Mundin. “The programme is now well underway, and we look forward to reaching our endpoint of developing novel compounds in this disease area much sooner than originally planned. The team is now even better placed to support our existing and new partners focused on ubiquitin system drug discovery.”